@FierceBiotech: ICYMI: $GSK's new Boston collaboration chief goes 'anti-pharma' as he prowls for partners. Article | Follow @FierceBiotech
@JohnCFierce: In diabetes, everybody is trying to beat everybody on next steps. Which is why Afrezza continues to stand out as a lonely effort. | Follow @JohnCFierce
@DamianFierce: $KMDA won't let a little thing like missing its endpoints in PhII/III derail a regulatory filing. More | Follow @DamianFierce
@EmilyMFierce: Infant Fingerprinting Could Help Track Vaccinations. MIT Technology Review story | Follow @EmilyMFierce
> Lexington, MA's iSpecimen, an eBay-like outfit that helps biotech researchers find and purchase tissue samples, closed an $8 million B round. News
> TransCelerate BioPharma, a nonprofit created by some of the world's largest drugmakers, has unveiled a recommended approach for how to protect patient privacy when sharing clinical study reports. Release
> Aradigm ($ARDM) picked up the FDA's fast-track designation for Pulmaquin, its Phase III treatment for chronic lung infections. More
> Biotech rEVO Biologics--formerly GTC Biotherapeutics--has scaled down its IPO ambitions, planning to raise $50 million at between $13 and $15 per share after first filing for a $75 million debut. Story
Medical Device News
@FierceMedDev: Researchers develop self-powered pacemaker system based on automatic wristwatch. Article | Follow @FierceMedDev
@VarunSaxena2: Per Capita Medicare Spending Is Actually Falling. More from the NYT | Follow @VarunSaxena2
@MichaelGFierce: Artificial virus promises effective drug delivery and gene therapy. FierceDrugDelivery story | Follow @MichaelGFierce
@EmilyWFierce: Fingerprint scanning system could help track children's vaccinations in developing countries. More from MIT Technology Review | Follow @EmilyWFierce
> AdvaMed says FDA proposed rule would result in more PMAs, device reclassifications. More
> Four lessons about the orthopedics industry from the CEO of group purchasing organization Amerinet. Editor's corner
> Propeller Health gets $14.5M Series B for smart inhaler, app combo. Article
Pharma News
@FiercePharma: Tops on FPMarketing Weds: Can Sanofi/Regeneron's new data one-up Amgen in megablockbuster PCSK9 field? Article | Follow @FiercePharma
@EricPFierce: Agents in EU seize €10M worth of counterfeit drugs, as well as cash and luxury cars, arrest a dozen. FiercePharmaManufacturing story | Follow @EricPFierce
@CarlyHFierce: ICYMI yesterday: Sanofi's dengue shot ups serotype 2 protection rate in final trial. FierceVaccines story | Follow @CarlyHFierce
> AstraZeneca pressed Obama for help resisting Pfizer's tax-cutting buyout bid. Article
> NICE slaps unusual rules on Alexion's pricey Soliris after atypical cost review. More
> Payers beware: Bristol-Myers prices PD-1 cancer med at $143,000 in Japan. Story
Vaccines News
> FDA rushes J&J, NewLink Genetics Ebola vaccines to clinical trials. Article
> Study: Old HIV pediatric vaccines might provide protection after all. Item
> Amid Bexsero negotiations, Novartis medical director slams U.K. vaccine assessment system. More
> Sanofi's dengue shot ups serotype 2 protection rate in final trial. Story
> Amgen submits melanoma-fighter T-Vec to EMA on the heels of its FDA filing. Report
Pharma Manufacturing News
> Theratechnologies returns HIV product Egrifta to U.S. Item
> Wockhardt expects to resolve most FDA concerns within the year. Report
> China sweeps up gang that made and sold 90M toxic capsules. More
> Actavis production not meeting demand for new version of Alzheimer's drug. Story
> Xellia lays out $100M expansion plan for new U.S. facility. Article